MacroGenics Statistics
Total Valuation
MacroGenics has a market cap or net worth of $968.28 million. The enterprise value is $772.44 million.
| Market Cap | 968.28M |
| Enterprise Value | 772.44M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
MacroGenics has 62.03 million shares outstanding. The number of shares has increased by 0.81% in one year.
| Shares Outstanding | 62.03M |
| Shares Change (YoY) | +0.81% |
| Shares Change (QoQ) | -1.28% |
| Owned by Insiders (%) | 2.61% |
| Owned by Institutions (%) | 99.85% |
| Float | 52.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.48 |
| Forward PS | 14.87 |
| PB Ratio | 6.34 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.15 |
| EV / EBITDA | 140.29 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.22.
| Current Ratio | 4.48 |
| Quick Ratio | 4.28 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 6.17 |
| Debt / FCF | n/a |
| Interest Coverage | -5.33 |
Financial Efficiency
Return on equity (ROE) is -5.80% and return on invested capital (ROIC) is -90.17%.
| Return on Equity (ROE) | -5.80% |
| Return on Assets (ROA) | -2.80% |
| Return on Capital (ROIC) | -90.17% |
| Revenue Per Employee | $173,301 |
| Profits Per Employee | -$26,720 |
| Employee Count | 339 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 6.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +128.55% in the last 52 weeks. The beta is 2.11, so MacroGenics's price volatility has been higher than the market average.
| Beta (1Y) | 2.11 |
| 52-Week Price Change | +128.55% |
| 50-Day Moving Average | 16.96 |
| 200-Day Moving Average | 9.55 |
| Relative Strength Index (RSI) | 44.03 |
| Average Volume (30 Days) | 1,579,353 |
Short Selling Information
The latest short interest is 6.45 million, so 10.39% of the outstanding shares have been sold short.
| Short Interest | 6.45M |
| Short Previous Month | 5.60M |
| Short % of Shares Out | 10.39% |
| Short % of Float | 12.36% |
| Short Ratio (days to cover) | 3.58 |
Income Statement
In the last 12 months, MacroGenics had revenue of $58.75 million and -$9.06 million in losses. Loss per share was -$0.15.
| Revenue | 58.75M |
| Gross Profit | 50.53M |
| Operating Income | -168.24M |
| Pretax Income | -9.06M |
| Net Income | -9.06M |
| EBITDA | 5.51M |
| EBIT | -7.63M |
| Loss Per Share | -$0.15 |
Balance Sheet
The company has $229.81 million in cash and $33.97 million in debt, giving a net cash position of $195.83 million or $3.16 per share.
| Cash & Cash Equivalents | 229.81M |
| Total Debt | 33.97M |
| Net Cash | 195.83M |
| Net Cash Per Share | $3.16 |
| Equity / Book Value | 152.61M |
| Book Value Per Share | 2.46 |
| Working Capital | 195.23M |
Cash Flow
In the last 12 months, operating cash flow was -$78.21 million and capital expenditures -$1.70 million, giving a free cash flow of -$79.91 million.
| Operating Cash Flow | -78.21M |
| Capital Expenditures | -1.70M |
| Free Cash Flow | -79.91M |
| FCF Per Share | -$1.29 |
Margins
Gross margin is 86.00%, with operating and profit margins of -286.38% and -15.42%.
| Gross Margin | 86.00% |
| Operating Margin | -286.38% |
| Pretax Margin | -15.42% |
| Profit Margin | -15.42% |
| EBITDA Margin | 9.37% |
| EBIT Margin | -12.98% |
| FCF Margin | -136.01% |
Dividends & Yields
MacroGenics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.81% |
| Shareholder Yield | -0.81% |
| Earnings Yield | -0.94% |
| FCF Yield | -8.25% |
Analyst Forecast
The average price target for MacroGenics is $21.50, which is 37.73% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.50 |
| Price Target Difference | 37.73% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 17.89% |
| EPS Growth Forecast (5Y) | 53.42% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MacroGenics has an Altman Z-Score of -0.29. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.29 |
| Piotroski F-Score | n/a |